Clinical Trials Browser

Phase 1/2 × Interventional × ulixertinib × Clear all

NCT01781429 2020-03-20

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Phase 1/2 Completed

136 enrolled 25 charts

Other solid neoplasm

Advanced Solid Tumors

NCT02296242 2019-01-29

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Phase 1/2 Completed

53 enrolled 16 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute